Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Roth MKM analyst Jonathan Aschoff maintains Cellectar Biosciences (NASDAQ:CLRB) with a Buy and raises the price target from ...
Oppenheimer analyst Jeff Jones reiterates Cellectar Biosciences (NASDAQ:CLRB) with a Outperform and raises the price target ...
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of...
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on rev...
Cellectar Biosciences reports positive Phase 1 trial results for iopofosine I 131 in head and neck squamous cell carcinoma, ach...
Roth MKM analyst Jonathan Aschoff reiterates Cellectar Biosciences (NASDAQ:CLRB) with a Buy and maintains $20 price target.
Complete Remission rate of 64% and Overall Response Rate of 73% demonstrated in highly refractory patients Durability of ...
